A case of convergent evolution: Several viral and bacterial pathogens hijack RSK kinases through a common linear motif.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
01 02 2022
Historique:
accepted: 29 11 2021
entrez: 29 1 2022
pubmed: 30 1 2022
medline: 26 2 2022
Statut: ppublish

Résumé

Microbes have been coevolving with their host for millions of years, exploiting host resources to their own benefit. We show that viral and bacterial pathogens convergently evolved to hijack cellular mitogen-activated protein kinase (MAPK) p90-ribosomal S6-kinases (RSKs). Theiler's virus leader (L) protein binds RSKs and prevents their dephosphorylation, thus maintaining the kinases active. Recruitment of RSKs enables L-protein-mediated inhibition of eukaryotic translation initiation factor 2 alpha kinase 2 (EIF2AK2 or PKR) and stress granule formation. Strikingly, ORF45 protein of Kaposi's sarcoma-associated herpesvirus (KSHV) and YopM protein of

Identifiants

pubmed: 35091472
pii: 2114647119
doi: 10.1073/pnas.2114647119
pmc: PMC8812568
pii:
doi:

Substances chimiques

Immediate-Early Proteins 0
Ribosomal Protein S6 Kinases, 90-kDa EC 2.7.11.1
Mitogen-Activated Protein Kinase Kinases EC 2.7.12.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2022 the Author(s). Published by PNAS.

Déclaration de conflit d'intérêts

Competing interest statement: Y.H. received a salary from Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan, while working as guest scientist at the Université Catholique de Louvain. The company had no influence on the research project.

Références

J Virol. 2001 Sep;75(17):7811-7
pubmed: 11483724
J Biol Chem. 2011 Dec 2;286(48):41171-41182
pubmed: 21994950
J Biol Chem. 2003 May 16;278(20):18514-23
pubmed: 12626518
PLoS Pathog. 2016 Jun 14;12(6):e1005660
pubmed: 27300509
J Virol. 2014 Jun;88(12):7024-35
pubmed: 24719417
Nat Cell Biol. 2001 Jul;3(7):667-74
pubmed: 11433299
Cancer Res. 1996 Oct 15;56(20):4620-4
pubmed: 8840974
Infect Immun. 2010 Aug;78(8):3529-39
pubmed: 20515922
Biochem J. 2012 Jan 15;441(2):553-69
pubmed: 22187936
J Mol Biol. 2001 Sep 28;312(4):807-21
pubmed: 11575934
Bioinformatics. 2015 Jun 15;31(12):2043-5
pubmed: 25788624
PLoS One. 2015 Jul 21;10(7):e0133190
pubmed: 26196674
Front Microbiol. 2018 Oct 12;9:2448
pubmed: 30369921
Curr Opin Struct Biol. 2015 Jun;32:91-101
pubmed: 25863584
Virulence. 2014;5(7):761-71
pubmed: 25513777
Trends Biochem Sci. 2011 Mar;36(3):159-69
pubmed: 21146412
Chem Rev. 2014 Jul 9;114(13):6589-631
pubmed: 24773235
Nat Rev Microbiol. 2009 Nov;7(11):787-97
pubmed: 19806153
EMBO J. 1996 Oct 1;15(19):5191-201
pubmed: 8895564
PLoS Pathog. 2016 Dec 2;12(12):e1006035
pubmed: 27911947
Cell Rep. 2014 Jun 12;7(5):1729-1739
pubmed: 24882001
J Biol Chem. 2009 May 15;284(20):13958-13968
pubmed: 19304659
Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19837-42
pubmed: 18077417
Structure. 2018 Feb 6;26(2):282-294.e6
pubmed: 29395785
Mol Biosyst. 2012 Jan;8(1):268-81
pubmed: 21909575
J Virol. 2004 Apr;78(8):4357-62
pubmed: 15047849
J Virol. 2011 Sep;85(18):9614-22
pubmed: 21752908
PLoS Biol. 2019 Jun 24;17(6):e3000341
pubmed: 31233486
Mol Cell Proteomics. 2012 Apr;11(4):M111.012088
pubmed: 22167269
J Virol. 2019 Sep 12;93(19):
pubmed: 31292248
J Virol. 2009 Nov;83(21):11223-32
pubmed: 19710133
Nature. 2021 Aug;596(7873):583-589
pubmed: 34265844
PLoS One. 2010 Oct 05;5(10):
pubmed: 20957203
J Virol. 2015 Jan;89(1):195-207
pubmed: 25320298
Infect Immun. 2010 Jun;78(6):2584-98
pubmed: 20368345
J Virol. 2008 Feb;82(4):1838-50
pubmed: 18057234
Cell Host Microbe. 2016 Sep 14;20(3):296-306
pubmed: 27569559
J Virol. 2010 Dec;84(24):12538-48
pubmed: 20881039

Auteurs

Frédéric Sorgeloos (F)

Virology Unit (VIRO), de Duve Institute, Université Catholique de Louvain, B-1200 Brussels, Belgium.

Michael Peeters (M)

Virology Unit (VIRO), de Duve Institute, Université Catholique de Louvain, B-1200 Brussels, Belgium.
Viral Diseases, Infectious Diseases in Humans, Sciensano 1050 Brussels, Belgium.

Yohei Hayashi (Y)

Virology Unit (VIRO), de Duve Institute, Université Catholique de Louvain, B-1200 Brussels, Belgium.
Frontier Sciences Unit, Department of Medical Innovations, Otsuka Pharmaceutical Co., Ltd., Tokushima 771-0192, Japan.

Fabian Borghese (F)

Virology Unit (VIRO), de Duve Institute, Université Catholique de Louvain, B-1200 Brussels, Belgium.

Nicolas Capelli (N)

Virology Unit (VIRO), de Duve Institute, Université Catholique de Louvain, B-1200 Brussels, Belgium.

Melissa Drappier (M)

Virology Unit (VIRO), de Duve Institute, Université Catholique de Louvain, B-1200 Brussels, Belgium.

Teresa Cesaro (T)

Virology Unit (VIRO), de Duve Institute, Université Catholique de Louvain, B-1200 Brussels, Belgium.

Didier Colau (D)

Brussels Branch, Ludwig Institute for Cancer Research, B-1200 Brussels, Belgium.

Vincent Stroobant (V)

Brussels Branch, Ludwig Institute for Cancer Research, B-1200 Brussels, Belgium.

Didier Vertommen (D)

Protein Phosphorylation Unit (PHOS), de Duve Institute, Université Catholique de Louvain, B-1200 Brussels, Belgium.
Mass spectrometry platform (MASSPROT), de Duve Institute, Université Catholique de Louvain, B-1200 Brussels, Belgium.

Grégory de Bodt (G)

Virology Unit (VIRO), de Duve Institute, Université Catholique de Louvain, B-1200 Brussels, Belgium.

Stéphane Messe (S)

Virology Unit (VIRO), de Duve Institute, Université Catholique de Louvain, B-1200 Brussels, Belgium.

Ignasi Forné (I)

Molecular Biology, Biomedical Centre, Faculty of Medicine, Ludwig-Maximilians-Universität München, 82152 Martinsried, Germany.

Felix Mueller-Planitz (F)

Molecular Biology, Biomedical Centre, Faculty of Medicine, Ludwig-Maximilians-Universität München, 82152 Martinsried, Germany.
Faculty of Medicine Carl Gustav Carus, Institute of Physiological Chemistry, Technische Universität Dresden, 01307 Dresden, Germany.

Jean-François Collet (JF)

Welbio, B-1200 Brussels, Belgium.
Biochemistry Unit (BCHM), de Duve Institute, Université Catholique de Louvain, B-1200 Brussels, Belgium.

Thomas Michiels (T)

Virology Unit (VIRO), de Duve Institute, Université Catholique de Louvain, B-1200 Brussels, Belgium; thomas.michiels@uclouvain.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH